Detection of human cytomegalovirus-specific T lymphocytes in human blood: Comparison of two methods

Cytotherapy

Volumn 10, Issue 8, 2008, Pages 834-841

  Schermann, C M ^a   Fischer, G ^b   Witt, V ^c   Kurz, M ^b   Potschger U ^d   Fritsch, G ^d  

^a INTERCELL AG   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

^c ST ANNA CHILDREN S HOSPITAL   (Austria)

^d CHILDREN'S CANCER RESEARCH INSTITUTE   (Austria)

Author keywords

Cytokine secretion assay; Human cytomegalovirus; Major histocompatibility complex class I tetramers; Multicolor flow cytometry analysis

Indexed keywords

CYTOMEGALOVIRUS ANTIGEN PP65; GAMMA INTERFERON; IMMUNOGLOBULIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; TETRAMER;

ANTIVIRAL THERAPY; ARTICLE; ASSAY; BLOOD SAMPLING; CAUCASIAN; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE RELEASE; EFFECTOR CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; IN VITRO STUDY; NORMAL HUMAN; PRIORITY JOURNAL; RELIABILITY; SENSITIVITY AND SPECIFICITY; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; VIRUS REACTIVATION; VOLUNTEER;

EID: 57949113717     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1080/14653240802474315     Document Type: Article

References (23)

1. Aubert, G., Hassan-Walker, AF Madrigal, JA et al. (2001) Cytomegalovirus-specific cellular immune responses and viremia in recipients of allogeneic stem cell transplants. J Infect Dis, 184, pp. 55-63.
2. Einsele, H., Ehninger, G. Hebart, H. et al. (1995) PCR monitoring after BMT to reduce the incidence of CMV disease and the duration and side effects of antiviral therapy. Blood, 86, pp. 2815-2820.
3. Ljungman, P., Engelhard, D. Link, H. et al. (1992) Treatment of interstitial pneumonitis due to cytomegalovirus with ganciclovir and intravenous immune globulin: Experience of European Bone Marrow Transplant Group. Clin Infect Dis, 14, pp. 831-835.
4. Boeckh, M., Bowden, RA Gooley, T. et al. (1999) Successful modification of a pp65 antigenemia-based early treatment strategy for prevention of cytomegalovirus disease in allogeneic bone marrow transplant recipients. Blood, 93, pp. 1781-1782.
5. Andrei, G., De Clercq, E. and Snoeck, R. (2008) Novel inhibitors of human CMV. Curr Opin Investig Drugs, 9, pp. 132-145.
6. Boeckh, M., Leisenring, W. Riddell, SR et al. (2003) Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: Importance of viral load and T-cell immunity. Blood, 101, pp. 407-414.
7. Tomonari, A., Iseki, T. Takahashi, JO et al. (2004) Ganciclovir-related neutropenia after preemptive therapy for cytomegalovirus infection: comparison between cord blood and bone marrow transplantation. Ann Hematol, 83, pp. 573-577.
8. Salzberger, B., Bowden, RA Hackman, RC et al. (1997) Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: Risk factors and outcome. Blood, 90, pp. 2502-2508.
9. Altman, JD, Moss, PA Goulder, PJ et al. (1996) Phenotypic analysis of antigen-specific T lymphocytes. Science, 274, pp. 94-96.
10. Kern, F., Bunde, T. Faulhaber, N. et al. (2002) Cytomegalovirus (CMV) phosphoprotein 65 makes a large contribution to shaping the T cell repertoire in CMV-exposed individuals. J Infect Dis, 185, pp. 1709-1716.
11. + T cells based on cytokine secretion. Methods, 31, pp. 150-159.
12. Wlodkovic, D., Skommer, J. and Darzynkiewicz, Z. (2008) Syto probes in the cytometry of tumor cell death. Cytometry, 73, pp. 496-507.
13. Wlodkovic, D., Skommer, J., Hillier, C. and Darzynkiewicz, Z. (2008) Multi parameter detection of apoptosis using red-excitable SYTO probes. Cytometry, 73, pp. 563-569.
14. Bland, JM and Altman, DG. (1999) Measuring agreement in method comparison studies. Stat Methods Med Res, 8, pp. 135-160.
15. Altman, DG, Machin, D., Trevor, N. and Gardner, MJ. (2001) Statistics with Confidence. BMJ Books
16. Middeldorp, JM, Jongsma, J. Ter Haar, A et al. (1984) Conditions for the detection of IgM and IgG antibodies against cytomegalovirus early and late antigens by ELISA. J Clin Microbiol, 20, pp. 763-771.
17. + T-lymphocyte immune responses to human cytomegalovirus pp65 in persons sharing HLA-A*02 HLA-B*07 alleles. Hum Immunol, 64, pp. 440-452.
18. Diamond, DJ, York, J. Sun, JY et al. (1997) Development of a candidate HLA-A*0201 restricted peptide-based vaccine against human cytomegalovirus infection. Blood, 90, pp. 1751-1767.
19. + virus specific cytotoxic T lymphocytes. J Med Virol, 43, pp. 103-110.
20. Mashishi, T. and Gray, CM. (2002) The ELISPOT assay: An easily transferable method for measuring cellular responses and identifying T cell epitopes. Clin Chem Lab Med, 40, pp. 903-910.
21. + T cells. Immunobiology, 100, pp. 3690-3697.
22. Cwynarski, K., Ainsworth, J. Cobbold, M. et al. (2001) Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation. Blood, 97, pp. 1232-1240.
23. + T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection. Blood, 98, pp. 1358-1364.